Skip to main content
. 2017 Feb 15;8(15):25021–25031. doi: 10.18632/oncotarget.15335

Table 1. Demographic, clinical and neuropsychological data of the subjects in this study.

MDD-aMCI(n=12) aMCI(n=13) Controls(n=14) PValue
Age (y) 69.5 ± 10.3 72.7 ± 8.5 64.7 ± 7.0 0.319c
Gender (M/F) 5/7 5/8 4/10 0.764b
Education (y) 11 (13-9.3) 9 (10.5 - 3) 10 (12-6) 0.309a
MMSE/30 27.2 ± 1.7 21.9 ± 4.9 27 (29.3-27) 0.041a*
MoCA/30 22.5 ± 3.3 17.9 ± 5.0 25.5 ± 5.7 0.014c*
AVLT-immediate recall (n) 4.2 ± 2.1 3.6 ± 1.4 7.3 ± 1.7 0.024c*
AVLT-delayed recall (n) 5 (7.0-4.3) 2.9 ±3.3 9.9 ± 2.6 0.004a**
AVLT-recognition (n) 7 (12.5-4.3) 7.5 ±3.7 11.3 ± 2.4 0.089a
CDR (score) 0.5 0.5 0 -
CDT (score) 3 (3.0-2.0) 2 (2.5-1.5) 3 (3.0-2.75) (7.0-4.3) 0.031a*

Mean ± standard deviation; Median and inter-quartile range [M (QU-QL)].

a k-independent samples nonparametric tests; b chi square test; c analysis of variance;

* P < 0.05, ** P < 0.01;

Abbreviations: MDD-aMCI, Major Depression Disorder and Amnestic Mild Cognitive Impairment; aMCI, Amnestic Mild Cognitive Impairment; n, number; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; AVLT, Auditory Verbal Learning Test (AVLT); CDR, Clinical Dementia Rating; CDT, Clock Drawing Test.